Global regulatory strength Cliantha has completed inspections by major global regulators (FDA, EU agencies, MHRA, ANVISA, WHO, CAP, NABL, etc.) and operates across India and North America with a footprint in three countries, signaling strong compliance readiness for multinational CRO collaborations and expansion of outsourced trials.

Full-spectrum CRO From early phase BA/BE and Phase I to late phase Phase II-IV, along with Bioanalytical, IVRT/IVPT, Biometrics, Medical Services, Allergy Testing and Veterinary therapeutics, Cliantha offers integrated services that can be bundled to win end-to-end development contracts from pharma and biotech clients.

Strategic partnerships Recent collaborations with Intelligent Bio Solutions for PK studies and with Social Palette Inc. for lead generation indicate a proactive approach to expanding service relevance (regulatory-ready PK work and demand generation) and targeting adjacent life sciences segments.

Scale and credibility With over 21 years in the industry and a workforce of 1500+ professionals, combined with a revenue range of 100M–250M, Cliantha positions itself as a mid-to-large CRO capable of handling sizable trials, offering reliability to sponsors seeking experienced partners.

Growth opportunities The company’s global sites, bioanalytical laboratories, and diversification into consumer clinical research and veterinary therapeutics present cross-selling opportunities to sponsors seeking broader clinical capabilities, quality assurances, and regional capabilities to support global trials.